Literature DB >> 20188174

Cancer as a reprogramming-like disease: implications in tumor development and treatment.

Andrés Castellanos1, Carolina Vicente-Dueñas, Elena Campos-Sánchez, Juan Jesús Cruz, Francisco Javier García-Criado, María Begoña García-Cenador, Pedro A Lazo, Jesús Pérez-Losada, Isidro Sánchez-García.   

Abstract

Cancer is a clonal malignant disease originated in a single cell and characterized by the accumulation of partially differentiated cells that are phenotypically reminiscent of normal stages of differentiation. Given the fact that human cancer is diagnosed at later stages and cannot be monitored during its natural evolution, the origin of tumors has been a subject of continuing discussion. Animal models provide a means to determine the identity of the cell-of-origin leading to malignancy and to develop new treatments. Recent findings in mice have shown that cancer stem cells could arise through a reprogramming-like mechanism, suggesting that genetic lesions that initiate the cancer process might be dispensable for tumor progression and maintenance. This review addresses the impact of these results toward a better understanding of carcinogenesis and proposes research avenues for tackling these issues in the future.

Entities:  

Mesh:

Year:  2010        PMID: 20188174     DOI: 10.1016/j.semcancer.2010.02.001

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  43 in total

Review 1.  Stem cells in mammary development and carcinogenesis: implications for prevention and treatment.

Authors:  Gabriela Dontu; Suling Liu; Max S Wicha
Journal:  Stem Cell Rev       Date:  2005       Impact factor: 5.739

Review 2.  Killing time for cancer stem cells (CSC): discovery and development of selective CSC inhibitors.

Authors:  María Pérez-Caro; Isidro Sánchez-García
Journal:  Curr Med Chem       Date:  2006       Impact factor: 4.530

Review 3.  Normal and neoplastic stem cells.

Authors:  Irving L Weissman
Journal:  Novartis Found Symp       Date:  2005

4.  Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors.

Authors:  Kazutoshi Takahashi; Shinya Yamanaka
Journal:  Cell       Date:  2006-08-10       Impact factor: 41.582

Review 5.  The cancer stem cell hypothesis: a work in progress.

Authors:  Brenton Thomas Tan; Christopher Yongchul Park; Laurie Elizabeth Ailles; Irving L Weissman
Journal:  Lab Invest       Date:  2006-10-30       Impact factor: 5.662

6.  Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content.

Authors:  Salvatore Pece; Daniela Tosoni; Stefano Confalonieri; Giovanni Mazzarol; Manuela Vecchi; Simona Ronzoni; Loris Bernard; Giuseppe Viale; Pier Giuseppe Pelicci; Pier Paolo Di Fiore
Journal:  Cell       Date:  2010-01-08       Impact factor: 41.582

7.  Conversion of mature B cells into T cells by dedifferentiation to uncommitted progenitors.

Authors:  César Cobaleda; Wolfram Jochum; Meinrad Busslinger
Journal:  Nature       Date:  2007-09-12       Impact factor: 49.962

Review 8.  The biology of cancer stem cells.

Authors:  Neethan A Lobo; Yohei Shimono; Dalong Qian; Michael F Clarke
Journal:  Annu Rev Cell Dev Biol       Date:  2007       Impact factor: 13.827

Review 9.  Chronic myeloid leukaemia as a model of disease evolution in human cancer.

Authors:  Junia V Melo; David J Barnes
Journal:  Nat Rev Cancer       Date:  2007-06       Impact factor: 60.716

Review 10.  Molecular heterogeneity of breast carcinomas and the cancer stem cell hypothesis.

Authors:  John Stingl; Carlos Caldas
Journal:  Nat Rev Cancer       Date:  2007-10       Impact factor: 60.716

View more
  16 in total

1.  Xenopatients 2.0: reprogramming the epigenetic landscapes of patient-derived cancer genomes.

Authors:  Javier A Menendez; Tomás Alarcón; Bruna Corominas-Faja; Elisabet Cuyàs; Eugeni López-Bonet; Angel G Martin; Luciano Vellon
Journal:  Cell Cycle       Date:  2014-01-09       Impact factor: 4.534

2.  MALT lymphoma meets stem cells.

Authors:  Carolina Vicente-Dueñas; César Cobaleda; José Ángel Martínez-Climent; Isidro Sánchez-García
Journal:  Cell Cycle       Date:  2012-07-24       Impact factor: 4.534

3.  The Warburg effect version 2.0: metabolic reprogramming of cancer stem cells.

Authors:  Javier A Menendez; Jorge Joven; Sílvia Cufí; Bruna Corominas-Faja; Cristina Oliveras-Ferraros; Elisabet Cuyàs; Begoña Martin-Castillo; Eugeni López-Bonet; Tomás Alarcón; Alejandro Vazquez-Martin
Journal:  Cell Cycle       Date:  2013-04-02       Impact factor: 4.534

4.  Epigallocatechin gallate inhibits sphere formation of neuroblastoma BE(2)-C cells.

Authors:  Noriyuki Nishimura; Tri Budi Hartomo; Thi Van Huyen Pham; Myeong Jin Lee; Tomoto Yamamoto; Satoru Morikawa; Daiichiro Hasegawa; Hiroki Takeda; Keiichiro Kawasaki; Yoshiyuki Kosaka; Nobuyuki Yamamoto; Ikuko Kubokawa; Takeshi Mori; Tomoko Yanai; Akira Hayakawa; Yasuhiro Takeshima; Kazumoto Iijima; Masafumi Matsuo; Hisahide Nishio
Journal:  Environ Health Prev Med       Date:  2011-09-10       Impact factor: 3.674

5.  Metastatic breast cancer cells in the bone marrow microenvironment: novel insights into oncoprotection.

Authors:  Shyam A Patel; Meneka A Dave; Raghav G Murthy; Karim Y Helmy; Pranela Rameshwar
Journal:  Oncol Rev       Date:  2011-06-01

6.  Basal/HER2 breast carcinomas: integrating molecular taxonomy with cancer stem cell dynamics to predict primary resistance to trastuzumab (Herceptin).

Authors:  Begoña Martin-Castillo; Cristina Oliveras-Ferraros; Alejandro Vazquez-Martin; Silvia Cufí; José Manuel Moreno; Bruna Corominas-Faja; Ander Urruticoechea; Ángel G Martín; Eugeni López-Bonet; Javier A Menendez
Journal:  Cell Cycle       Date:  2012-01-15       Impact factor: 4.534

7.  Loss of p53 exacerbates multiple myeloma phenotype by facilitating the reprogramming of hematopoietic stem/progenitor cells to malignant plasma cells by MafB.

Authors:  Carolina Vicente-Dueñas; Inés González-Herrero; María Begoña García Cenador; Francisco Javier García Criado; Isidro Sánchez-García
Journal:  Cell Cycle       Date:  2012-09-14       Impact factor: 4.534

8.  Nuclear reprogramming of luminal-like breast cancer cells generates Sox2-overexpressing cancer stem-like cellular states harboring transcriptional activation of the mTOR pathway.

Authors:  Bruna Corominas-Faja; Sílvia Cufí; Cristina Oliveras-Ferraros; Elisabet Cuyàs; Eugeni López-Bonet; Ruth Lupu; Tomás Alarcón; Luciano Vellon; Juan Manuel Iglesias; Olatz Leis; Ángel G Martín; Alejandro Vazquez-Martin; Javier A Menendez
Journal:  Cell Cycle       Date:  2013-08-21       Impact factor: 4.534

9.  A novel molecular mechanism involved in multiple myeloma development revealed by targeting MafB to haematopoietic progenitors.

Authors:  Carolina Vicente-Dueñas; Isabel Romero-Camarero; Inés González-Herrero; Esther Alonso-Escudero; Fernando Abollo-Jiménez; Xiaoyu Jiang; Norma C Gutierrez; Alberto Orfao; Nieves Marín; Luisa María Villar; Ma Carmen Fernández Criado; Belén Pintado; Teresa Flores; Diego Alonso-López; Javier De Las Rivas; Rafael Jiménez; Francisco Javier García Criado; María Begoña García Cenador; Izidore S Lossos; César Cobaleda; Isidro Sánchez-García
Journal:  EMBO J       Date:  2012-08-17       Impact factor: 11.598

10.  A New Strategy to Find Targets for Anticancer Therapy: Chemokine CXCL14/BRAK Is a Multifunctional Tumor Suppressor for Head and Neck Squamous Cell Carcinoma.

Authors:  Ryu-Ichiro Hata
Journal:  ISRN Otolaryngol       Date:  2012-11-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.